Hypoxia-inducible factor-1α expression in macrophages promotes development of atherosclerosis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 36, Issue 9, 2016, Pages 1782-1790

  Aarup, Annemarie ^a   Pedersen, Tanja X ^a   Junker, Nanna ^a   Christoffersen, Christina ^a,b   Bartels, Emil D ^b   Madsen, Marie ^a   Nielsen, Carsten H ^a   Nielsen, Lars B ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Mental Health Services CPH   (Denmark)

Author keywords

Apoptosis; Atherosclerosis; Hypoxia; Hypoxia inducible factor 1 ; Macrophage

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; APOLIPOPROTEIN E; AUTACOID; CHOLESTEROL; GLUCOSE; HIF1A PROTEIN, MOUSE; LOW DENSITY LIPOPROTEIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; BONE MARROW CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; GENE EXPRESSION; GLUCOSE TRANSPORT; IMMUNOHISTOCHEMISTRY; LASER MICRODISSECTION; MACROPHAGE; MACROPHAGE MIGRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; AORTIC DISEASE; ATHEROSCLEROTIC PLAQUE; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CELL CULTURE; CELL HYPOXIA; CELL MOTION; DEFICIENCY; DISEASE COURSE; DISEASE MODEL; FOAM CELL; GENETIC PREDISPOSITION; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHENOTYPE; SIGNAL TRANSDUCTION; THORACIC AORTA;

ANIMALS; AORTA, THORACIC; AORTIC DISEASES; APOLIPOPROTEINS E; APOPTOSIS; ATHEROSCLEROSIS; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; CELL HYPOXIA; CELL MOVEMENT; CELLS, CULTURED; CHOLESTEROL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FOAM CELLS; GENETIC PREDISPOSITION TO DISEASE; GLUCOSE; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INFLAMMATION MEDIATORS; MICE, INBRED C57BL; MICE, KNOCKOUT; PHENOTYPE; PLAQUE, ATHEROSCLEROTIC; RECEPTORS, LDL; SIGNAL TRANSDUCTION;

EID: 84979662970     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.116.307830     Document Type: Article

References (68)

1. Mendis S, Puska P, Norrving B, Section A-Cardiovascular diseases (CVDs) due to atherosclerosis. In: Global Atlas on Cardiovascular Disease Prevention and Control 2011 Geneva World Health Organization 8 14
2. Narula J, Garg P, Achenbach S, Motoyama S, Virmani R, Strauss HW, Arithmetic of vulnerable plaques for noninvasive imaging. Nat Clin Pract Cardiovasc Med 2008 5 suppl 2 S2 10. doi: 10.1038/ncpcardio1247
3. Takahashi K, Takeya M, Sakashita N, Multifunctional roles of macrophages in the development and progression of atherosclerosis in humans and experimental animals. Med Electron Microsc 2002 35 179 203. doi: 10.1007/s007950200023
4. Libby P, Inflammation in atherosclerosis. Nature 2002 420 868 874. doi: 10.1038/nature01323
5. Wolfs IM, Stöger JL, Goossens P, Pöttgens C, Gijbels MJ, Wijnands E, van der Vorst EP, van Gorp P, Beckers L, Engel D, Biessen EA, Kraal G, van Die I, Donners MM, de Winther MP, Reprogramming macrophages to an anti-inflammatory phenotype by helminth antigens reduces murine atherosclerosis. FASEB J 2014 28 288 299. doi: 10.1096/fj.13-235911
6. Babaev VR, Hebron KE, Wiese CB, Toth CL, Ding L, Zhang Y, May JM, Fazio S, Vickers KC, Linton MF, Macrophage deficiency of Akt2 reduces atherosclerosis in Ldlr null mice. J Lipid Res 2014 55 2296 2308. doi: 10.1194/jlr.M050633
7. -/- mice develop fibrous carotid plaques. J Am Heart Assoc 2014 3 e001232. doi: 10.1161/JAHA.114.001232
8. Libby P, Ridker PM, Hansson GK, Progress and challenges in translating the biology of atherosclerosis. Nature 2011 473 317 325. doi: 10.1038/nature10146
9. Li AC, Glass CK, The macrophage foam cell as a target for therapeutic intervention. Nat Med 2002 8 1235 1242. doi: 10.1038/nm1102-1235
10. Hultén LM, Levin M, The role of hypoxia in atherosclerosis. Curr Opin Lipidol 2009 20 409 414. doi: 10.1097/MOL.0b013e3283307be8
11. Astrup P, Effects of hypoxia and of carbon monoxide exposures on experimental atherosclerosis. Ann Intern Med 1969 71 426 427
12. Garbarsch C, Matthiessen ME, Helin P, Lorenzen I, Arteriosclerosis and hypoxia. I. Gross and microscopic changes in rabbit aorta induced by systemic hypoxia. Histochemical studies. J Atheroscler Res 1969 9 283 294
13. Carmeliet P, Jain RK, Angiogenesis in cancer and other diseases. Nature 2000 407 249 257. doi: 10.1038/35025220
14. Sluimer JC, Gasc JM, van Wanroij JL, Kisters N, Groeneweg M, Sollewijn Gelpke MD, Cleutjens JP, van den Akker LH, Corvol P, Wouters BG, Daemen MJ, Bijnens AP, Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. J Am Coll Cardiol 2008 51 1258 1265. doi: 10.1016/j.jacc.2007.12.025
15. Björnheden T, Levin M, Evaldsson M, Wiklund O, Evidence of hypoxic areas within the arterial wall in vivo. Arterioscler Thromb Vasc Biol 1999 19 870 876
16. Björnheden T, Bondjers G, Oxygen consumption in aortic tissue from rabbits with diet-induced atherosclerosis. Arteriosclerosis 1987 7 238 247
17. Morrison ES, Scott RF, Kroms M, Frick J, Glucose degradation in normal and atherosclerotic aortic intima-media. Atherosclerosis 1972 16 175 184
18. Semenza GL, Hypoxia-inducible factor 1: Oxygen homeostasis and disease pathophysiology. Trends Mol Med 2001 7 345 350
19. Wang GL, Jiang BH, Rue EA, Semenza GL, Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995 92 5510 5514
20. Semenza GL, Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003 3 721 732. doi: 10.1038/nrc1187
21. Salceda S, Caro J, Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 1997 272 22642 22647
22. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, Kaelin WG Jr, HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science 2001 292 464 468. doi: 10.1126/science.1059817
23. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ, The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999 399 271 275. doi: 10.1038/20459
24. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, Kaelin WG, Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000 2 423 427. doi: 10.1038/35017054
25. Sutter CH, Laughner E, Semenza GL, Hypoxia-inducible factor 1alpha protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations. Proc Natl Acad Sci USA 2000 97 4748 4753. doi: 10.1073/pnas.080072497
26. Tanimoto K, Makino Y, Pereira T, Poellinger L, Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J 2000 19 4298 4309. doi: 10.1093/emboj/19.16.4298
27. Weidemann A, Johnson RS, Biology of HIF-1alpha. Cell Death Differ 2008 15 621 627. doi: 10.1038/cdd.2008.12
28. Gao L, Chen Q, Zhou X, Fan L, The role of hypoxia-inducible factor 1 in atherosclerosis. J Clin Pathol 2012 65 872 876. doi: 10.1136/jclinpath-2012-200828
29. Jiang G, Li T, Qiu Y, Rui Y, Chen W, Lou Y, RNA interference for HIF-1alpha inhibits foam cells formation in vitro. Eur J Pharmacol 2007 562 183 190. doi: 10.1016/j.ejphar.2007.01.066
30. Parathath S, Mick SL, Feig JE, Joaquin V, Grauer L, Habiel DM, Gassmann M, Gardner LB, Fisher EA, Hypoxia is present in murine atherosclerotic plaques and has multiple adverse effects on macrophage lipid metabolism. Circ Res 2011 109 1141 1152. doi: 10.1161/CIRCRESAHA.111.246363
31. Na TY, Lee HJ, Oh HJ, Huh S, Lee IK, Lee MO, Positive cross-Talk between hypoxia inducible factor-1 and liver X receptor induces formation of triglyceride-loaded foam cells. Arterioscler Thromb Vasc Biol 2011 31 2949 2956. doi: 10.1161/ATVBAHA.111.235788
32. Cramer T, Yamanishi Y, Clausen BE, Förster I, Pawlinski R, Mackman N, Haase VH, Jaenisch R, Corr M, Nizet V, Firestein GS, Gerber HP, Ferrara N, Johnson RS, HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 2003 112 645 657
33. Peyssonnaux C, Cejudo-Martin P, Doedens A, Zinkernagel AS, Johnson RS, Nizet V, Cutting edge: Essential role of hypoxia inducible factor-1alpha in development of lipopolysaccharide-induced sepsis. J Immunol 2007 178 7516 7519
34. Peyssonnaux C, Datta V, Cramer T, Doedens A, Theodorakis EA, Gallo RL, Hurtado-Ziola N, Nizet V, Johnson RS, HIF-1alpha expression regulates the bactericidal capacity of phagocytes. J Clin Invest 2005 115 1806 1815. doi: 10.1172/JCI23865
35. Ben-Shoshan J, Afek A, Maysel-Auslender S, Barzelay A, Rubinstein A, Keren G, George J, HIF-1alpha overexpression and experimental murine atherosclerosis. Arterioscler Thromb Vasc Biol 2009 29 665 670. doi: 10.1161/ATVBAHA.108.183319
36. Liu D, Lei L, Desir M, Huang Y, Cleman J, Jiang W, Fernandez-Hernando C, Di Lorenzo A, Sessa WC, Giordano FJ, Smooth muscle hypoxia-inducible factor 1 links intravascular pressure and atherosclerosis-brief report. Arterioscler Thromb Vasc Biol 2016 36 442 445. doi: 10.1161/ATVBAHA.115.306861
37. Higashida T, Kanno H, Nakano M, Funakoshi K, Yamamoto I, Expression of hypoxia-inducible angiogenic proteins (hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and E26 transformation-specific-1) and plaque hemorrhage in human carotid atherosclerosis. J Neurosurg 2008 109 83 91. doi: 10.3171/JNS/2008/109/7/0083
38. Vink A, Schoneveld AH, Lamers D, Houben AJ, van der Groep P, van Diest PJ, Pasterkamp G, HIF-1 alpha expression is associated with an atheromatous inflammatory plaque phenotype and upregulated in activated macrophages. Atherosclerosis 2007 195 e69 e75. doi: 10.1016/j.atherosclerosis.2007.05.026
39. Luque A, Turu M, Juan-Babot O, Cardona P, Font A, Carvajal A, Slevin M, Iborra E, Rubio F, Badimon L, Krupinski J, Overexpression of hypoxia/inflammatory markers in atherosclerotic carotid plaques. Front Biosci 2008 13 6483 6490
40. Silvola JM, Saraste A, Forsback S, Laine VJ, Saukko P, Heinonen SE, Ylä-Herttuala S, Roivainen A, Knuuti J, Detection of hypoxia by [18F]EF5 in atherosclerotic plaques in mice. Arterioscler Thromb Vasc Biol 2011 31 1011 1015. doi: 10.1161/ATVBAHA.110.221440
41. Arteel GE, Thurman RG, Yates JM, Raleigh JA, Evidence that hypoxia markers detect oxygen gradients in liver: Pimonidazole and retrograde perfusion of rat liver. Br J Cancer 1995 72 889 895
42. Preacher KJ, Hayes AF, Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behav Res Methods 2008 40 879 891
43. Kjeldsen K, Astrup P, Wanstrup J, Reversal of rabbit atheromatosis by hyperoxia. J Atheroscler Res 1969 10 173 178
44. Heughan C, Niinikoski J, Hunt TK, Oxygen tensions in lesions of experimental atherosclerosis of rabbits. Atherosclerosis 1973 17 361 367
45. Chaudhari SM, Sluimer JC, Koch M, Deficiency of HIF1 in antigen-presenting cells aggravates atherosclerosis and type 1 T-helper cell responses in mice. Arterioscler Thromb Vasc Biol 2015 35 2316 2325. doi: 10.1161/ATVBAHA.115.306171
46. Rahtu-Korpela L, Määttä J, Dimova EY, Hörkkö S, Gylling H, Walkinshaw G, Hakkola J, Kivirikko KI, Myllyharju J, Serpi R, Koivunen P, Hypoxia-inducible factor prolyl 4-hydroxylase-2 inhibition protects against development of atherosclerosis. Arterioscler Thromb Vasc Biol 2016 36 608 617. doi: 10.1161/ATVBAHA.115.307136
47. Tabas I, Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: The importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vasc Biol 2005 25 2255 2264. doi: 10.1161/01.ATV.0000184783.04864.9f
48. Schrijvers DM, De Meyer GR, Herman AG, Martinet W, Phagocytosis in atherosclerosis: Molecular mechanisms and implications for plaque progression and stability. Cardiovasc Res 2007 73 470 480. doi: 10.1016/j.cardiores.2006.09.005
49. Seimon T, Tabas I, Mechanisms and consequences of macrophage apoptosis in atherosclerosis. J Lipid Res 2009 50 suppl S382 S387. doi: 10.1194/jlr.R800032-JLR200
50. Piret JP, Mottet D, Raes M, Michiels C, Is HIF-1alpha a pro-or an anti-Apoptotic protein? Biochem Pharmacol 2002 64 889 892
51. Bentzon JF, Falk E, Atherosclerotic lesions in mouse and man: Is it the same disease? Curr Opin Lipidol 2010 21 434 440. doi: 10.1097/MOL.0b013e32833ded6a
52. Llodrá J, Angeli V, Liu J, Trogan E, Fisher EA, Randolph GJ, Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc Natl Acad Sci USA 2004 101 11779 11784. doi: 10.1073/pnas.0403259101
53. Trogan E, Feig JE, Dogan S, Rothblat GH, Angeli V, Tacke F, Randolph GJ, Fisher EA, Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc Natl Acad Sci USA 2006 103 3781 3786. doi: 10.1073/pnas.0511043103
54. Asplund A, Ostergren-Lundén G, Camejo G, Stillemark-Billton P, Bondjers G, Hypoxia increases macrophage motility, possibly by decreasing the heparan sulfate proteoglycan biosynthesis. J Leukoc Biol 2009 86 381 388. doi: 10.1189/jlb.0908536
55. Shatrov VA, Sumbayev VV, Zhou J, Brüne B, Oxidized low-density lipoprotein (oxLDL) triggers hypoxia-inducible factor-1alpha (HIF-1alpha) accumulation via redox-dependent mechanisms. Blood 2003 101 4847 4849. doi: 10.1182/blood-2002-09-2711
56. Hellwig-Bürgel T, Rutkowski K, Metzen E, Fandrey J, Jelkmann W, Interleukin-1beta and tumor necrosis factor-Alpha stimulate DNA binding of hypoxia-inducible factor-1. Blood 1999 94 1561 1567
57. Thornton RD, Lane P, Borghaei RC, Pease EA, Caro J, Mochan E, Interleukin 1 induces hypoxia-inducible factor 1 in human gingival and synovial fibroblasts. Biochem J 2000 350 pt 1 307 312
58. Movafagh S, Crook S, Vo K, Regulation of hypoxia-inducible factor-1a by reactive oxygen species: New developments in an old debate. J Cell Biochem 2015 116 696 703. doi: 10.1002/jcb.25074
59. Semenza GL, Roth PH, Fang HM, Wang GL, Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 1994 269 23757 23763
60. Folco EJ, Sheikine Y, Rocha VZ, Christen T, Shvartz E, Sukhova GK, Di Carli MF, Libby P, Hypoxia but not inflammation augments glucose uptake in human macrophages: Implications for imaging atherosclerosis with 18fluorine-labeled 2-deoxy-D-glucose positron emission tomography. J Am Coll Cardiol 2011 58 603 614. doi: 10.1016/j.jacc.2011.03.044
61. Freemerman AJ, Johnson AR, Sacks GN, Milner JJ, Kirk EL, Troester MA, Macintyre AN, Goraksha-Hicks P, Rathmell JC, Makowski L, Metabolic reprogramming of macrophages: Glucose transporter 1 (GLUT1)-mediated glucose metabolism drives a proinflammatory phenotype. J Biol Chem 2014 289 7884 7896. doi: 10.1074/jbc.M113.522037
62. Tawakol A, Singh P, Mojena M, HIF-1 and PFKFB3 mediate a tight relationship between proinflammatory activation and anerobic metabolism in atherosclerotic macrophages. Arterioscler Thromb Vasc Biol 2015 35 1463 1471. doi: 10.1161/ATVBAHA.115.305551
63. Wilcox JN, Subramanian RR, Sundell CL, Tracey WR, Pollock JS, Harrison DG, Marsden PA, Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscler Thromb Vasc Biol 1997 17 2479 2488
64. Detmers PA, Hernandez M, Mudgett J, Deficiency in inducible nitric oxide synthase results in reduced atherosclerosis in apolipoprotein E-deficient mice. J Immunol 2000 165 3430 3435
65. Martinez FO, Helming L, Gordon S, Alternative activation of macrophages: An immunologic functional perspective. Annu Rev Immunol 2009 27 451 483. doi: 10.1146/annurev.immunol.021908.132532
66. Holdstock L, Meadowcroft AM, Maier R, Johnson BM, Jones D, Rastogi A, Zeig S, Lepore JJ, Cobitz AR, Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia. J Am Soc Nephrol 2016 27 1234 1244. doi: 10.1681/ASN.2014111139
67. Besarab A, Chernyavskaya E, Motylev I, Shutov E, Kumbar LM, Gurevich K, Chan DT, Leong R, Poole L, Zhong M, Saikali KG, Franco M, Hemmerich S, Yu KH, Neff TB, Roxadustat (FG-4592): Correction of anemia in incident dialysis patients. J Am Soc Nephrol 2016 27 1225 1233. doi: 10.1681/ASN.2015030241
68. Besarab A, Provenzano R, Hertel J, Zabaneh R, Klaus SJ, Lee T, Leong R, Hemmerich S, Yu KH, Neff TB, Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol Dial Transplant 2015 30 1665 1673. doi: 10.1093/ndt/gfv302